This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -22.37% and 4.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?
by Kinjel Shah
Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
by Zacks Equity Research
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
Lilly (LLY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Lilly (LLY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
by Zacks Equity Research
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
by Zacks Equity Research
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
by Zacks Equity Research
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
by Kinjel Shah
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
by Zacks Equity Research
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.